# The Benefit of Hemodialysis Plus Hemoperfusion on Mortality

> **NCT03227770** · NA · COMPLETED · sponsor: **Xinhua Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 1362 (actual)

## Conditions studied

- End-stage Renal Disease

## Interventions

- **DEVICE:** hemoperfusion combined with hemodialysis
- **DEVICE:** hemodialysis

## Key facts

- **NCT ID:** NCT03227770
- **Lead sponsor:** Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 1362 (ACTUAL)
- **Last updated:** 2022-08-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03227770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03227770, "The Benefit of Hemodialysis Plus Hemoperfusion on Mortality". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03227770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*